Union health minister Ghulam Nabi Azad on Wednesday said that there is a need to strike balance between the interests of all the stakeholders with regard to the country’s regulatory policy on clinical trials, noting that innovation should be encouraged. Pharma firms have complained that India's new regulations for clinical trials were too stringent and some of them are in the process of moving trials overseas despite the higher costs involved.
Source: Financial Express
News on Other Repro Health
This is a collection of news clippings from differnt newspapers on other reproductive health issues